Pharmacology and advances in the field of EGFR inhibitors for the treatment of NSCLC

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorFakhoury, Omar
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentDrimba, László
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptKlinikai Központ::Kenézy Gyula Campus
dc.contributor.opponentdeptÁltalános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.date.accessioned2024-01-15T09:28:55Z
dc.date.available2024-01-15T09:28:55Z
dc.date.created2023-10-05
dc.description.abstractSince the approval of the first epidermal growth factor receptor (EGFR) inhibitor for the treatment of non-small cell lung cancer (NSCLC) in 2003, great strides have been made in this field of targeted therapy to address the global burden of lung cancer, which is the most diagnosed and the leading cause of cancer-related death worldwide. This thesis investigates the pharmacological aspects of older generations of EGFR inhibitors, including their mechanism of action, pharmacokinetics, clinical efficacy, and adverse effects, as well as the resistance mechanisms of tumors to these drugs. Despite improvements in therapy due to the emergence of osimertinib and other third generation EGFR inhibitors, resistance remains a global concern which mandates further research. Therefore, many therapeutic strategies which have been heavily investigated, as well as novel agents such as antibody drug conjugates, vaccines, monoclonal antibodies, and ultimately, fourth generation EGFR inhibitors, have been described in this work, aiming to shed light on the advances that can revolutionize the landscape of NSCLC therapy.
dc.description.courseáltalános orvos
dc.description.courselangangol
dc.description.degreeegységes, osztatlan
dc.format.extent53 pages
dc.identifier.urihttps://hdl.handle.net/2437/365003
dc.language.isoen
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectEGFR inhibitors
dc.subjectNSCLC
dc.subject.dspaceDEENK Témalista::Medicine::Pharmacology
dc.titlePharmacology and advances in the field of EGFR inhibitors for the treatment of NSCLC
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
THESIS FINAL SUBMISSION.pdf
Méret:
1.28 MB
Formátum:
Adobe Portable Document Format
Leírás:
Thesis
Megjelenítés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nincs kép
Név:
license.txt
Méret:
1.94 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Theses (Faculty of Medicine)